Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
4(66.7%)
N/A
2(33.3%)
6Total
Phase 4(4)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04430868Not ApplicableUnknown

Lifestyle Redesign For Schizophrenia

Role: lead

NCT04040998Not ApplicableCompleted

Compensatory Cognitive Training For Schizophrenia

Role: lead

NCT00545467Phase 4Completed

Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents

Role: collaborator

NCT00837707Phase 4Unknown

Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia

Role: lead

NCT00621998Phase 4Completed

Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia

Role: lead

NCT00331825Phase 4Completed

Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism

Role: lead

All 6 trials loaded